GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

The following is a summary of "Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic ...

LOUISVILLE, Ky. -- More than half of patients with newly diagnosed metastatic kidney cancer responded to a novel drug ...

Fecal microbiota transplantation has significantly improved progression-free survival in patients with metastatic renal cell ...

Researchers have found an association between baseline circulating tumor cell count and survival in metastatic ...

Ratios of visceral proteins can act as independent indicators for both overall and progression-free survival in patients with ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...

The FDA recently approved the combination of inavolisib, fulvestrant, and palbociclib in this patient population.

The INAVO120 study reveals that the three-drug therapy inavolisib, palbociclib and fulvestrant significantly delays cancer ...

The combination of THIO and Libtayo has shown promising results among patients with advanced checkpoint inhibitor-resistant ...

THURSDAY, Oct. 31, 2024 (HealthDay News) -- Inavolisib plus palbociclib-fulvestrant yields significantly longer ...

The treatment-related adverse events, however, were higher with the radiotherapy-TKI combination among patients with ...